Not Signed In -
Naloxone Injection |
Narcan |
Clinical Trial: Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
This study has been completed.
Purpose
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Opioid-Related Disorders Substance-Related Disorders | Drug: Buprenorphine/naloxone | Phase II |
MedlinePlus related topics: Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Uncontrolled
Official Title: Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence
Eligibility
Ages Eligible for Study: 19 Years - 57 Years, Genders Eligible for Study: Both
Criteria
Please contact site for information.
Location Information
Pennsylvania
University of Pennsylvania, Philadelphia, Pennsylvania, 19104 6178, United States
Study chairs or principal investigators
Charles O'Brien, M.D., Ph.D., Principal Investigator, PDVAMC Treatment Research Center
More Information
Study ID Numbers: NIDA-3-0012-2; Y01-3-0012-2
Record last reviewed: December 2002
Last Updated: December 3, 2004
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000353
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: December 2002
Last Updated: December 3, 2004
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000353
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
